Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 479

1.

Role of new drugs for management of atrial fibrillation.

Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM.

Ann Pharmacother. 2012 Dec;46(12):1656-70. doi: 10.1345/aph.1R155. Epub 2012 Dec 18. Review.

PMID:
23249869
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.

Yates SW.

Hosp Pract (1995). 2011 Oct;39(4):7-16. doi: 10.3810/hp.2011.10.918. Review.

PMID:
22056819
4.

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

O'Dell KM, Igawa D, Hsin J.

Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Review.

PMID:
22417716
5.

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

McKeage K.

Pharmacoeconomics. 2012 Sep 1;30(9):841-55. doi: 10.2165/11209130-000000000-00000. Review.

PMID:
22734683
6.

Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.

Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB.

Eur Heart J. 2013 Aug;34(31):2464-71. doi: 10.1093/eurheartj/eht135. Epub 2013 Apr 17.

7.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

8.

Dronedarone for the treatment of atrial fibrillation and atrial flutter.

Maund E, McKenna C, Sarowar M, Fox D, Stevenson M, Pepper C, Palmer S, Woolacott N.

Health Technol Assess. 2010 Oct;14(Suppl. 2):55-62. doi: 10.3310/hta14suppl2/08. Review.

9.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

10.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
11.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.

Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.

BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.

12.

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Review.

PMID:
21740079
13.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
14.

Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.

von Schéele B, Fernandez M, Hogue SL, Kwong WJ.

Ann Pharmacother. 2013 May;47(5):671-85. doi: 10.1345/aph.1R411. Epub 2013 Apr 19. Review.

PMID:
23606551
15.

Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.

Baker WL, Phung OJ.

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):711-9. Epub 2012 Aug 21. Review.

16.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
17.

Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.

Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.

Clin Ther. 2013 Jul;35(7):967-984.e2. doi: 10.1016/j.clinthera.2013.05.011.

PMID:
23870607
18.

Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.

Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):472-9. doi: 10.1161/CIRCOUTCOMES.112.965251. Epub 2012 Jun 26.

19.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
20.

[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].

Röther J, Laufs U.

Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S55-8. doi: 10.1055/s-0030-1249210. Epub 2010 Mar 10. Review. German.

PMID:
20221980
Items per page

Supplemental Content

Write to the Help Desk